These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25669642)

  • 1. Trial geography, pharmacogenetics, and global drug development.
    Schuck RN; Florian J; Charlab R; Pacanowski M
    Clin Pharmacol Ther; 2015 Mar; 97(3):218-20. PubMed ID: 25669642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics in drug development.
    McCarthy AD; Kennedy JL; Middleton LT
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1579-88. PubMed ID: 16096107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size estimation of multiregional clinical trials with heterogeneous variability across regions.
    Wu YJ; Tan TS; Chow SC; Hsiao CF
    J Biopharm Stat; 2014; 24(2):254-71. PubMed ID: 24605968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilizing pharmacogenomic analyses during clinical trials in drug development.
    Bienfait KL; Shaw PM; Murthy G; Warner AW
    Pharmacogenomics; 2013 Jul; 14(10):1227-35. PubMed ID: 23859576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials.
    Wang SJ; James Hung HM
    J Biopharm Stat; 2012 Sep; 22(5):879-93. PubMed ID: 22946937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of clinical efficacy.
    Michelson S; Sehgal A; Friedrich C
    Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global requirements for DNA sample collections: results of a survey of 204 ethics committees in 40 countries.
    Ricci DS; Broderick ED; Tchelet A; Hong F; Mayevsky S; Mohr DM; Schaffer ME; Warner AW; Hakkulinen P; Snapir A
    Clin Pharmacol Ther; 2011 Apr; 89(4):554-61. PubMed ID: 21346753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Affymetrix DMET platform and pharmacogenetics in drug development.
    Deeken J
    Curr Opin Mol Ther; 2009 Jun; 11(3):260-8. PubMed ID: 19479659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective.
    Ando Y; Hamasaki T
    Pharm Stat; 2010; 9(3):190-200. PubMed ID: 20737442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size allocation in multiregional equivalence studies.
    Liao JJZ; Yu Z; Li Y
    Pharm Stat; 2018 Sep; 17(5):570-577. PubMed ID: 29911346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving clinical trial sampling for future research - an international approach: outcomes and next steps from the DIA future use sampling workshop 2011.
    Warner AW; Bienfait KL; Bledsoe M; Burckart G; Flamion B; Knoppers B; Nelsen AJ; Rudman A; Sieffert NJ; Uyama Y
    Pharmacogenomics; 2013 Jan; 14(1):103-12. PubMed ID: 23252952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of geographical variation on clinical outcomes of cardiovascular trials.
    Mentz RJ; Kaski JC; Dan GA; Goldstein S; Stockbridge N; Alonso-Garcia A; Ruilope LM; Martinez FA; Zannad F; Pitt B; Fiuzat M; O'Connor CM
    Am Heart J; 2012 Sep; 164(3):303-12. PubMed ID: 22980295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the use of pharmacogenetics in cancer treatment and clinical trials.
    Robert J; Le Morvan V; Giovannetti E; Peters GJ;
    Eur J Cancer; 2014 Oct; 50(15):2532-43. PubMed ID: 25103456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International differences in treatment effect: do they really exist and why?
    Pocock S; Calvo G; Marrugat J; Prasad K; Tavazzi L; Wallentin L; Zannad F; Alonso Garcia A
    Eur Heart J; 2013 Jun; 34(24):1846-52. PubMed ID: 23475529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size determination for a specific region in a multiregional trial.
    Ko FS; Tsou HH; Liu JP; Hsiao CF
    J Biopharm Stat; 2010 Jul; 20(4):870-85. PubMed ID: 20496211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.